Ori Biotech and CRL Enhance CAR-T Production
Ori Biotech and CRL partner to optimize CAR-T production, reducing labor by 70%, costs by 50%, and process time by ...
- Latest
- Trending
Ori Biotech and CRL partner to optimize CAR-T production, reducing labor by 70%, costs by 50%, and process time by ...
Biotech sees stable funding as 2024 venture capital and IPOs rise. Investors focus on late-stage assets amid economic challenges.
Legend Biotech reports significant revenue growth in Q2 2024, with strategic advancements in CAR-T therapies.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
E3technology enhances Empore™ membranes for better proteome sample prep, crucial for low-cell proteomics, say experts at UD and CDS Analytical.
Phage therapy, unlocking the potential of bacteria phages, is being used to treat antibiotic-resistant infections. It potentially saved a woman's ...
NextCure, Inc. (NXTC) is a biopharmaceutical company focused on novel immunomedicines. Strong financials, positive outlook, and promising pipeline.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.